Wockhardt and Biocon have come under the drug price regulator National Pharmaceutical Pricing Authority (NPPA) scanner for allegedly violating pricing norms. NPPA has initiated an investigation against two insulin analogue brands, Wockhardt’s Glaritus and Biocon’s Basalog, for selling the medicine without a price approval.
Insulin is an essential medicine under the price control of NPPA. Wockhardt and Biocon have introduced glargine formulation in the market with their respective brand names. The pricing authority has already written to both the domestic companies asking them to explain their move.
The Mumbai-based pharmaceutical and biotechnology major Wockhardt had launched Glaritus in February this year. The company confirmed that it has received a query from NPPA on Glaritus’ price approval and has also responded to it. According to Wockhardt, Glaritus (glargine) is a long-acting insulin analogue available in the market. Such analogues of insulin are not covered under the definition of ‘scheduled bulk drugs’ and hence Glaritus prices were not referred to NPPA.
Biotechnology major Biocon’s product Basalog was launched in May 2009. The Bangalore-based company says that while NPPA’s norms seek to establish ‘reasonable prices’ for essential and life saving drugs, their product Basalog is already priced at a significant discount to other marketed products. As per the company’s understanding, glargine does not fall under the scope and definition of NPPA. Biocon is in the process of clarifying its position to NPPA in accordance with Drug Price Control Order, 1995.
crackcrack
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
